Details:

Alternative Title:
Vaccine
Publisher's site:
http://dx.doi.org/10.1016/j.vaccine.2014.09.035
Personal Author:
Chen, Robert T. ; Carbery, Baevin ; Mac, Lisa ; Chapman, Louisa E. ; Condit, Richard C. ; ... More +
Chen, Robert T. ; Carbery, Baevin ; Mac, Lisa ; Chapman, Louisa E. ; Condit, Richard C. ; Excler, Jean-Louis ; Gurwith, Marc ; Hendry, Michael ; Khan, Arifa S. ; Khuri-Bulos, Najwa ; Klug, Bettina ; Robertson, Jim S. ; Seligman, Stephen J. ; Sheets, Rebecca ; Williamson, Anna-Lise Less -
Description:
Recombinant viral vectors provide an effective means for heterologous antigen expression in vivo and thus represent promising platforms for developing novel vaccines against human pathogens from Ebola to tuberculosis. An increasing number of candidate viral vector vaccines are entering human clinical trials. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to improve our ability to anticipate potential safety issues and meaningfully assess or interpret safety data, thereby facilitating greater public acceptance when licensed.
Subject:
[+]
Clinical Trials As Topic
Drug-Related Side Effects And Adverse Reactions
Drug Carriers
Genetic Vectors
Humans
International Cooperation
Vaccines, Synthetic
Viral Vaccines

Source:
Vaccine. 33(1):73-75.
Pubmed ID:
25305565
Pubmed Central ID:
PMC4568939
Document Type:
Journal Article
Funding:
CC999999/Intramural CDC HHS/United States
Collection(s):
CDC Public Access
Main Document Checksum:
[+]
urn:sha256:23bc374a69c9af80861d52baec6a6b2e959304c15ef59e81f93776af4eb7a135
File Type:

Supporting Files

• nihms720669.nxml

  bin

More +